CBE
MCID: CHR682
MIFTS: 42

Chronic Bilirubin Encephalopathy (CBE)

Categories: Metabolic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Chronic Bilirubin Encephalopathy

MalaCards integrated aliases for Chronic Bilirubin Encephalopathy:

Name: Chronic Bilirubin Encephalopathy 58 75
Bilirubin-Induced Neurological Dysfunction 58
Kernicterus Spectrum Disorder 58
Bind 58
Cbe 58
Ksd 58

Characteristics:


Prevelance:

1-9/100000 (Canada, Denmark, United States) 58

Age Of Onset:

Infancy,Neonatal 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Inborn errors of metabolism


Summaries for Chronic Bilirubin Encephalopathy

Orphanet: 58 A rare neurologic disease characterized by the chronic consequences of bilirubin toxicity in the globus pallidus, sub-thalamic nuclei, and other brain regions, after exposure to high levels of unconjugated bilirubin in the neonatal period. Symptoms begin after the acute phase of bilirubin encephalopathy in the first year of life, evolve slowly over several years, and include mild to severe extrapyramidal disturbances (especially dystonia and athetosis), auditory neuropathy spectrum disorder, and oculomotor and dental abnormalities.

MalaCards based summary: Chronic Bilirubin Encephalopathy, also known as bilirubin-induced neurological dysfunction, is related to von willebrand disease, type 2 and cold agglutinin disease. The drugs Apomorphine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include globus pallidus, brain and smooth muscle, and related phenotypes are prolonged neonatal jaundice and hepatic encephalopathy

Wikipedia: 75 Kernicterus is a bilirubin-induced brain dysfunction. The term was coined in 1904 by Christian Georg... more...

Related Diseases for Chronic Bilirubin Encephalopathy

Diseases in the Acute Bilirubin Encephalopathy family:

Chronic Bilirubin Encephalopathy

Diseases related to Chronic Bilirubin Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 877)
# Related Disease Score Top Affiliating Genes
1 von willebrand disease, type 2 11.1
2 cold agglutinin disease 11.1
3 retinoblastoma 11.0
4 myasthenia gravis 11.0
5 neuromyelitis optica 10.9
6 episodic ataxia 10.9
7 factor v leiden thrombophilia 10.9
8 helix syndrome 10.5
9 rapidly involuting congenital hemangioma 10.5
10 amyloidosis 10.5
11 human immunodeficiency virus type 1 10.5
12 major depressive disorder 10.4
13 kernicterus 10.4
14 encephalopathy 10.4
15 immune deficiency disease 10.4
16 hypolipoproteinemia 10.4
17 severe acute respiratory syndrome 10.4
18 herpes simplex 10.4
19 systemic lupus erythematosus 10.4
20 bilirubin metabolic disorder 10.4
21 lupus erythematosus 10.3
22 primary agammaglobulinemia 10.3
23 influenza 10.3
24 alzheimer disease, familial, 1 10.3
25 malaria 10.3
26 viral infectious disease 10.3
27 autoimmune disease 10.2
28 hepatitis c virus 10.2
29 iron metabolism disease 10.2
30 fetal anticonvulsant syndrome 10.2
31 amyotrophic lateral sclerosis 1 10.2
32 dengue disease 10.2
33 plasmodium falciparum malaria 10.2
34 leukemia 10.2
35 neuroblastoma 10.2
36 dengue virus 10.2
37 breast cancer 10.2
38 covid-19 10.2
39 cholera 10.2
40 hepatitis 10.2
41 lateral sclerosis 10.2
42 cytokine deficiency 10.2
43 henoch-schoenlein purpura 10.2
44 hepatitis c 10.2
45 turner syndrome 10.2
46 down syndrome 10.2
47 t-cell acute lymphoblastic leukemia 10.2
48 myeloid leukemia 10.2
49 ataxia with vitamin e deficiency 10.1
50 aspergillosis 10.1

Graphical network of the top 20 diseases related to Chronic Bilirubin Encephalopathy:



Diseases related to Chronic Bilirubin Encephalopathy

Symptoms & Phenotypes for Chronic Bilirubin Encephalopathy

Human phenotypes related to Chronic Bilirubin Encephalopathy:

58 30 (show all 21)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 prolonged neonatal jaundice 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006579
2 hepatic encephalopathy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002480
3 neonatal hyperbilirubinemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003265
4 abnormal auditory evoked potentials 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006958
5 intellectual disability 58 30 Frequent (33%) Frequent (79-30%)
HP:0001249
6 seizure 58 30 Frequent (33%) Frequent (79-30%)
HP:0001250
7 sensorineural hearing impairment 58 30 Frequent (33%) Frequent (79-30%)
HP:0000407
8 hypertonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001276
9 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
10 hemolytic anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001878
11 cerebral palsy 58 30 Frequent (33%) Frequent (79-30%)
HP:0100021
12 hypoalbuminemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003073
13 feeding difficulties 58 30 Frequent (33%) Frequent (79-30%)
HP:0011968
14 central apnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002871
15 abnormal thalamic mri signal intensity 58 30 Frequent (33%) Frequent (79-30%)
HP:0012696
16 kernicterus 58 30 Frequent (33%) Frequent (79-30%)
HP:0001343
17 conjunctival icterus 58 30 Frequent (33%) Frequent (79-30%)
HP:0032106
18 hypernatremia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003228
19 neonatal sepsis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0040187
20 visual gaze preference 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0025518
21 abnormal conjunctiva morphology 58 Frequent (79-30%)

Drugs & Therapeutics for Chronic Bilirubin Encephalopathy

Drugs for Chronic Bilirubin Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
2
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
3 Broncho-Vaxom Phase 4
4 Adjuvants, Immunologic Phase 4
5 Immunologic Factors Phase 4
6 Neurotransmitter Agents Phase 4
7 Dopamine agonists Phase 4
8 Dopamine Agents Phase 4
9 Emetics Phase 4
10 Gastrointestinal Agents Phase 4
11 Urinastatin Phase 4
12 HIV Protease Inhibitors Phase 4
13 Trypsin Inhibitors Phase 4
14 Serine Proteinase Inhibitors Phase 4
15 Pharmaceutical Solutions Phase 4
16
protease inhibitors Phase 4
17
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
18
Rimonabant Approved, Investigational Phase 3 168273-06-1, 158681-13-1 104850
19
Epoprostenol Approved Phase 3 61849-14-7, 35121-78-9 5282411
20
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
21
Sildenafil Approved, Investigational Phase 3 139755-83-2, 171599-83-0 5212 135398744
22
Iron Approved Phase 3 7439-89-6 29936
23
Rituximab Approved Phase 3 174722-31-7
24
Nitric Oxide Approved Phase 3 10102-43-9 145068
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
26
Arginine Approved, Investigational, Nutraceutical Phase 3 74-79-3 6322
27
Tezosentan Investigational Phase 3 180384-57-0
28
Apaziquone Investigational Phase 3 114560-48-4 5813717
29 Anti-Obesity Agents Phase 3
30 Phosphodiesterase Inhibitors Phase 3
31 Phosphodiesterase 5 Inhibitors Phase 3
32 Vasodilator Agents Phase 3
33 Citrate Phase 3
34 Blood Substitutes Phase 3
35
Epoetin Alfa Phase 3
36 Hematinics Phase 3
37 Antirheumatic Agents Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39
Citalopram Approved Phase 2 59729-32-7, 59729-33-8 2771
40
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181
41
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
42
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
43
Dexetimide Withdrawn Phase 2 21888-98-2 30843
44 Psychotropic Drugs Phase 2
45 Antidepressive Agents Phase 2
46 Serotonin Uptake Inhibitors Phase 2
47 Hormones Phase 2
48 Hormone Antagonists Phase 2
49 Antineoplastic Agents, Hormonal Phase 2
50
Abiraterone Acetate Phase 2 154229-18-2 9821849

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity Completed NCT03301155 Phase 4 Anaferon for children;Placebo
2 Prospective, Pivotal Unicentre, Randomized Double-bind, Placebo-controlled Study, to Evaluate Efficacy and Safety of Bacterial Lysates (Pulmonarom) in the Prevention of Respiratory Tract Infections Completed NCT00599417 Phase 4 Bacterial Lysates;placebo
3 Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Active, not recruiting NCT02940912 Phase 4 Apomorphine;Placebo
4 Multicenter, Double-bind, Randomised, Placebo Controlled Study of Ulinastatin in Severe Acute Pancreatitis Suspended NCT01132521 Phase 4 ulinastatin;placebo
5 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving Completed NCT00481975 Phase 3 rimonabant (SR141716)
6 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 With or Without Hypocaloric Diet in Obese Patients Completed NCT00481923 Phase 3 rimonabant (SR141716)
7 A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension. Completed NCT00159861 Phase 3 Sildenafil citrate
8 Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period. Completed NCT01154491 Phase 3 Ferric carboxymaltose;Erythropoietin;Placebo
9 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
10 L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial Terminated NCT00549575 Phase 3 L ARG;Placebo
11 A Phase 3 International, Double-Bind Trial Evaluating Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Terminated NCT01469221 Phase 3 Apaziquone;Placebo
12 An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer Completed NCT02283320 Phase 2 BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
13 A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder Completed NCT01020799 Phase 2 AZD7268;Escitalopram;Placebo capsules;Placebo tablets
14 An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01812746 Phase 2 BIND-014
15 An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer Completed NCT01792479 Phase 2 BIND-014
16 An Evolutionary Double Bind Phase II Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Eligible for Prostatectomy Not yet recruiting NCT05574712 Phase 2 Neoadjuvant treatment
17 A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck Terminated NCT02479178 Phase 2 BIND-014 (docetaxel nanoparticles for injectable suspension)
18 A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Completed NCT00605241 Phase 1 GSK598809
19 A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer Completed NCT01300533 Phase 1 BIND-014
20 Validation of Bilirubin Binding Capacity (BBC) Using AVIV Device Completed NCT02612207
21 CAN-BIND (Canadian Biomarker Integration Network for Depression): Long-Term Follow Up Study Completed NCT02998762
22 A Prospective, Multicenter, Randomized and Single Bind Trial. Influence of Laryngoscope Blade Material on Postoperative PHARYNGEAL AND LARYNGEAL Morbidity Following Scheduled OroTracheal Intubation Completed NCT01118533
23 The Ties That Bind: Evaluation of a Patient-worn Pulse Oximeter Compared to Traditional Pulse Oximetry on Loss of Signal Integrity in Pediatric Patients Completed NCT03187665
24 A Collaborative Investigation of Predictors of Relapse in Major Depressive Disorder: CAN-BIND-1 Extension Study Completed NCT02934334
25 Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5 and WP6) Part 2: a Neurobehavioural and MRI Study Recruiting NCT04668716
26 Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5) Part 1: a Multicentre Online Phenotyping and Neurobehavioural Data Collection Study Recruiting NCT04583917
27 Effect of Glutaraldehyde-based Desensitizer in the Control of Tooth Sensitivity and Tooth Color Post- Whitening : Clinical, Randomized,Double Bind and Split Mouth Study Recruiting NCT05309967

Search NIH Clinical Center for Chronic Bilirubin Encephalopathy

Genetic Tests for Chronic Bilirubin Encephalopathy

Anatomical Context for Chronic Bilirubin Encephalopathy

Organs/tissues related to Chronic Bilirubin Encephalopathy:

MalaCards : Globus Pallidus, Brain, Smooth Muscle, Prostate, Endothelial, T Cells, Lung

Publications for Chronic Bilirubin Encephalopathy

Articles related to Chronic Bilirubin Encephalopathy:

(show top 50) (show all 30069)
# Title Authors PMID Year
1
KAP is the neuronal organelle adaptor for Kinesin-2 KIF3AB and KIF3AC. 62
36200888 2022
2
Searching for drug leads targeted to the hydrophobic cleft of dengue virus capsid protein. 62
34894959 2022
3
Extraintestinal pathogenic Escherichia coli utilizes the surface-expressed elongation factor Tu to bind and acquire iron from holo-transferrin. 62
35443872 2022
4
The cytosolic iron-sulphur cluster assembly mechanism in grapevine is one target of a virulent Crinkler effector from Plasmopara viticola. 62
36071584 2022
5
Natural LILRB1 D1-D2 variants show frequency differences in populations and bind to HLA class I with various avidities. 62
35562487 2022
6
Divergent polo boxes in KKT2 bind KKT1 to initiate the kinetochore assembly cascade in Trypanosoma brucei. 62
36129769 2022
7
GATA4 and estrogen receptor alpha bind at SNPs rs9921222 and rs10794639 to regulate AXIN1 expression in osteoblasts. 62
35678873 2022
8
Cryo-EM structure shows how two IGF1 hormones bind to the human IGF1R receptor. 62
36332473 2022
9
MoS2 nanosheets effectively bind to the receptor binding domain of the SARS-CoV-2 spike protein and destabilize the spike-human ACE2 receptor interactions. 62
36382499 2022
10
Cisplatin toxicity is mediated by direct binding to TLR4 through a mechanism that is distinct from metal allergens. 62
36460345 2022
11
Recognition of cyclic dinucleotides and folates by human SLC19A1. 62
36265513 2022
12
Practical Guidance for Consensus Scoring and Force Field Selection in Protein-Ligand Binding Free Energy Simulations. 62
36399655 2022
13
The transcription factor E2A can bind to and cleave single-stranded immunoglobulin heavy chain locus DNA. 62
36434987 2022
14
Human 14-3-3 Proteins Site-selectively Bind the Mutational Hotspot Region of SARS-CoV-2 Nucleoprotein Modulating its Phosphoregulation. 62
36427566 2022
15
Replication Protein A Utilizes Differential Engagement of Its DNA-Binding Domains to Bind Biologically Relevant ssDNAs in Diverse Binding Modes. 62
36278947 2022
16
The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX. 62
36181774 2022
17
Characterization of antibody clones that bind exclusively to insoluble fibrin. 62
36239546 2022
18
Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune. 62
36430159 2022
19
Flavin Adenine Dinucleotide (FAD) and Pyridoxal 5'-Phosphate (PLP) Bind to Sox9 and Alter the Expression of Key Pancreatic Progenitor Transcription Factors. 62
36430529 2022
20
Low-Molecular Weight Small Molecules Can Potently Bind RNA and Affect Oncogenic Pathways in Cells. 62
36322830 2022
21
1,4-Dideoxy-1,4-imino-D- and L-lyxitol-based inhibitors bind to Golgi α-mannosidase II in different protonation forms. 62
36322142 2022
22
Synthesis and properties of oligodiaminogalactoses that bind to A-type oligonucleotide duplexes. 62
36222332 2022
23
Mcm2 promotes stem cell differentiation via its ability to bind H3-H4. 62
36354740 2022
24
Bacterial-Type Long-Chain Polyphosphates Bind Human Proteins in the Phosphatidylinositol Signaling Pathway. 62
35909349 2022
25
Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARγ. 62
36358965 2022
26
ZER1 Contributes to the Carcinogenic Activity of High-Risk HPV E7 Proteins. 62
36346242 2022
27
High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire. 62
36441829 2022
28
Discovery of small molecules that target a tertiary-structured RNA. 62
36413497 2022
29
Better assessment of neonatal jaundice at home (BEAT Jaundice @home): protocol for a prospective, multicentre diagnostic study. 62
36396315 2022
30
Glycan-mediated interactions between bacteria, rotavirus and the host cells provide an additional mechanism of antiviral defence. 62
36239669 2022
31
The Ties That Bind: Glial Transplantation in White Matter Ischemia and Vascular Dementia. 62
36357662 2022
32
Host and viral proteins involved in SARS-CoV-2 infection differentially bind heme. 62
36161737 2022
33
Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage. 62
36419093 2022
34
Polyol and sugar osmolytes stabilize the molten globule state of α-lactalbumin and inhibit amyloid fibril formation. 62
36096464 2022
35
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study. 62
35793696 2022
36
IgG fractions from patients with antiphospholipid syndrome and systemic lupus erythematosus bind to platelets, but do not affect collagen-induced platelet activation. 62
35394397 2022
37
The emerging importance of immunophilins in fibrosis development. 62
36302992 2022
38
The Sialyl Lewis X Glycan Receptor Facilitates Infection of Subtype H7 Avian Influenza A Viruses. 62
36125302 2022
39
Pathogenic Neisseria Bind the Complement Protein CFHR5 via Outer Membrane Porins. 62
36194022 2022
40
Viral infections and drug hypersensitivity. 62
36264263 2022
41
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. 62
33734021 2022
42
Insight into the C-terminal SH3 domain mediated binding of Drosophila Drk to Sos and Dos. 62
35952612 2022
43
Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk. 62
33769184 2022
44
Hold your horses: The receptor-binding domains of SARS-CoV-2, SARS-CoV, and hCoV-NL63 bind equine ACE2. 62
36206735 2022
45
Barley metallothionein isoforms, MT2b2 and MT4, differentially respond to photohormones in barley aleurone layer and their recombinant forms show different affinity for binding to zinc and cadmium. 62
36309886 2022
46
Topological zero-dimensional defect and flux states in three-dimensional insulators. 62
36184669 2022
47
Isolation of a Peptide That Binds to Pseudomonas aeruginosa Lytic Bacteriophage. 62
36312416 2022
48
The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis. 62
35979993 2022
49
Nucleophilic Thiol Proteins Bind Covalently to Abasic Sites in DNA. 62
35482010 2022
50
Anamnestic broadly reactive antibodies induced by H7N9 virus more efficiently bind to seasonal H3N2 strains. 62
36197079 2022

Variations for Chronic Bilirubin Encephalopathy

Expression for Chronic Bilirubin Encephalopathy

Search GEO for disease gene expression data for Chronic Bilirubin Encephalopathy.

Pathways for Chronic Bilirubin Encephalopathy

GO Terms for Chronic Bilirubin Encephalopathy

Sources for Chronic Bilirubin Encephalopathy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....